Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,475,399 papers from all fields of science
Search
Sign In
Create Free Account
allergovit
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Vaccines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
[Effect and safety analysis of Allergovit standardized mite allergen immunotherapy in patients with allergic rhinitis].
Xiaoming Zhao
,
Huiqing Wu
,
Lili Lin
,
Qianzu Liu
,
Xiaomin Li
,
B. Luo
Lin chuang er bi yan hou tou jing wai ke za zhi…
2013
Corpus ID: 46489716
OBJECTIVE To evaluate the effect and safety analysis of Allergovit standardized dust mite subcutaneous immunotherapy in patients…
Expand
2012
2012
Hypoallergenic high-dose immunotherapy proves effective and safe in a multicentre surveillance study
G. Hoheisel
,
E. Martín
,
B. Jaeschke
,
S. Thum-Oltmer
Allergo Journal
2012
Corpus ID: 68595048
AbstractBackground: The safety and efficacy of subcutaneous immunotherapy (SCIT) with the high-dose hypoallergenic preparations…
Expand
2006
2006
[Safety analysis of Allergovit immunotherapy in patients of allergic rhinitis].
Jianjun Chen
,
J. Xiang
,
W. Kong
,
H. Shu
,
Q. Shi
,
H. Tan
Lin chuang er bi yan hou ke za zhi = Journal of…
2006
Corpus ID: 11536640
OBJECTIVE To analyse the safety of Allergovit immunotherapy in patients of allergic rhinitis. METHOD Two hundred and fifty-six…
Expand
2005
2005
Kurzzeitimmuntherapie mit Allergoiden : Ergebnisse einer prospektiven, offenen Studie in der allergologischen Praxis
S. Thum-Oltmer
,
D. Ullrich
,
H. Meyer
,
D. MüLLER-SCHEVEN
2005
Corpus ID: 77422281
Background: Various controlled clinical trials have proven the efficacy and safety of a short-term specific immunotherapy (SIT…
Expand
2002
2002
[The influence of a three-year preseasonal specific immunotherapy on selected parameters of allergic inflammation in pollinosis patients].
A. Fal
,
K. Gietkiewicz
,
A. Obojski
,
W. Mędrala
,
J. Małolepszy
Pneumonologia i Alergologia Polska
2002
Corpus ID: 7741755
Specific immunotherapy (SIT) can in some cases influence the course of allergic inflammation (eosinophilia and ECP concentration…
Expand
2001
2001
[Evaluation of effectiveness and safety of three year immunotherapy with mixed grass pollen allergens].
K. Gietkiewicz
,
Andrzej M. Fal
,
Józef Małolepszy
Polskie Archiwum Medycyny Wewnetrznej
2001
Corpus ID: 40208367
BACKGROUND Specific immunotherapy (SIT) is probably the only causative treatment in allergic diseases including pollinosis. It is…
Expand
1997
1997
[Evaluation of the efficacy of immunotherapy with allergovit and catalet in patients with hay fever--multidrug evaluations].
T. Hofman
,
K. Buczyłko
,
P. Brewczyński
,
B. Kolasińska
Pneumonologia i Alergologia Polska
1997
Corpus ID: 20241966
UNLABELLED The aim of this study was to compare the efficacy of the immunotherapy by Allergovit and Catalet. 699 patient in age 5…
Expand
1997
1997
[Results of specific immunotherapy with Allergovit in patients with pollen allergy].
T. Hofman
Polski merkuriusz lekarski : organ Polskiego…
1997
Corpus ID: 46535860
The immunotherapy among patients with pollen allergy was performed by individuals composed Allergovit. The effects of this…
Expand
1996
1996
KURZ- UND MITTELFRISTIGE ERFOLGSKONTROLLE NACH DREIJAHRIGER HYPOSENSIBILISIERUNG MIT GRAMINEENPOLLEN-DEPOT-ALLERGOID (ALLERGOVIT)
E. Frank
,
B. Joppich
,
A. Distler
,
O. Cromwell
1996
Corpus ID: 79259273
1995
1995
[Efficacy and tolerance of allergenic extracts Allergovit and Novo-Helisen depot in immunotherapy of allergic diseases].
S. Chyrek-Borowska
,
A. Rogalewska
,
W. Szymański
,
I. Zlotnik
,
I. Michalska
Pneumonologia i Alergologia Polska
1995
Corpus ID: 34834623
The aim of this study was to evaluate the efficacy, tolerance and immunogenity of allergenic extracts: Allergovit and Novo…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required